Continuing Treatment With Bevacizumab Beyond Progression Improved PFS Compared With Chemo Alone For Patients With Recurrent Ovarian Cancer, Study Shows

Cancer Network (3/13, Fowler) reported, “Continuing treatment with bevacizumab (Avastin) beyond progression improved progression-free survival for patients with platinum-sensitive recurrent ovarian cancer compared with chemotherapy alone, according to data published in The Lancet Oncology.” The study results “sought to determine the value of continued bevacizumab treatment after progression following first-line treatment, suggesting this therapeutic path could be considered in clinical practice.”